Background. Rapidly growing mycobacteria (RGM) have been associated with various clinical syndromes in immunocompetent and immunocompromised hosts. The risk factors and outcomes of RGM infection in patients with cancer have not been clearly defined.
Rapidly growing mycobacteria (RGM) were defined by Runyon as mycobacteria that form colonies in subcultures in р7 days [1, 2] . They are ubiquitous in nature and can be found in soil, bioaerosols, and water. Several strains have intrinsic resistance to many antibiotics, which complicates treatment [3] .
RGM infections have emerged in 2 different clinical settings. Disease is described in apparently normal hosts who have an invasive procedure that introduces the organism [4] [5] [6] [7] [8] [9] [10] . Additionally, cases are found in hosts with either abnormal anatomy, such as bronchiectasis, or profound dysfunction of immune response, such as occurs after some cancer therapies or organ transplant [3, 11] . RGM infection is rare in human immunodeficiency virus (HIV)-infected patients, although they are predisposed to infection with other nontuberculous my-probable, possible infection, or contaminant on the basis of the American Thoracic Society and the Infectious Diseases Society of America criteria [13] . Catheter-related cases were defined according to published guidelines for evaluation of catheterrelated infections [14] . Disseminated infection was defined according to an article published elsewhere [11] and included patients with at least 1 of the following characteristics: (1) multiple cutaneous abscesses, (2) visceral involvement with or without skin manifestations, or (3) positive blood/bone marrow culture and clinical evidence of deep infection.
Microbiologic techniques. Blood cultures were performed using the BACTEC Plus aerobic/F bottles and Mycobacteria Growth Indicator tubes (BD Diagnostic Systems). Recommended volumes of blood per bottle were 8-10 mL for adults and 4-5 mL for children. Culture bottles were incubated for 5 days at 37ЊC. Indicator tubes were incubated for 42 days at 37ЊC. Positive cultures were grown on 7H11 and blood agar plates.
At MSKCC, deep respiratory specimens, such as bronchoalveolar washings, tracheal aspirates, and specimens of lung tissue, are commonly cultured for mycobacteria. Specimens from other sites, such as sputum, skin/soft tissue, and stool, were cultured for mycobacteria at the discretion of the clinician. These practices did not change throughout the study period. Cultures for mycobacteria followed standard techniques and were incubated for 6 weeks. Sterile specimens were inoculated directly into media. Nonsterile specimens were first decontaminated by treatment with 4% sodium hydroxide for 15 min.
All mycobacterial strains were sent to the Mayo Clinic for identification through sequencing analysis of the 16S ribosomal RNA gene [15] .
Literature review. We searched MEDLINE for English language articles published since 1980 with the following search terms: RGM, rapidly-growing, rapid-grower, nontuberculous, non-tuberculous, NTM, MOTT, mycobacteria, mycobacterium, chelonae, chelonei, abscessus, fortuitum, smegmatis, neoaurum, aurum, mucogenicum, oncologic, cancer, lymphoma, leukemia, myeloma, transplant, transplantation, and hematologic. Additional articles were obtained by checking references from selected studies and from review articles. We excluded 6 cases from 3 studies [16] [17] [18] in which dissemination was suspected but not proven. All of these had positive blood cultures with concurrent undiagnosed pulmonary nodules which resolved with routine empiric antimicrobial treatment. Only studies with a description of the demographic and/or clinical aspects of the cases were included. Abstracts not published as full papers were excluded. We extracted the following data from the selected papers: age, sex, RGM species, underlying cancer, additional underlying conditions, presence of central venous catheter (CVC), presence of neutropenia or lymphopenia, use of chemotherapy or corticosteroids, treatment, and outcome. Data analysis. The student's T test and x 2 tests were used for univariate comparisons when appropriate. In all analyses, a P value of !.05 was considered to indicate statistical significance. All probabilities were 2-tailed.
RESULTS

Cases at MSKCC
Demographic and clinical features of cases at MSKCC. During the 10-year period, there were 1913 positive mycobacterial cultures at MSKCC. Of these, 130 cultures from 39 patients grew RGM, including 28 with an underlying history of cancer (Table 1 ) and 11 without. The mean rate of RGM infection was 2.9 cases per 100,000 patient-days. In comparison, rates of Staphylococcus aureus, Escherichia coli, and Candida species bloodstream infections at MSKCC during the same period were 77, 90, and 31 cases per 100,000 patient-days, respectively.
Of the 28 patients with cancer, 17 (61%) were female and 11 (39%) were male. Twenty-one were adults, and 7 were pediatric patients. One patient had 2 different RGM species isolated in cultures during the time period, comprising 29 strains overall. Isolated species (Table 2) included Mycobacterium abscessus (13 patients), Mycobacterium fortuitum (9 patients), Mycobacterium mucogenicum (3 patients), Mycobacterium smegmatis, and Mycobacterium neoaurum. All isolates from blood cultures grew in standard aerobic blood culture bottles. All isolates from other sources grew in mycobacterial cultures.
The median age of adult patients was 62 years (range, 31-86 years). Ten were male, and 11 were female. Four (19%) had a history of hematologic malignancy, including 2 hematopoietic stem cell transplant (HSCT) recipients, and 17 (81%) had a history of a solid tumor. Of the 22 isolates, 13 (59%) arose from respiratory samples. Four (18%) were collected from skin/ soft-tissue samples, and 1 (5%) was collected from a CVC culture. One patient had positive cultures from respiratory samples, blood culture, and skin lesions.
Two patients were HIV infected; the first was a 58-year-old man with HIV infection (CD4 count, 180 cells/mm 3 ) and lymphoma who developed CVC infection with M. mucogenicum; the second was a 48-year-old man with HIV infection (CD4 count, 23 cells/mm 3 ) and Kaposi sarcoma with M. fortuitum in a stool specimen.
For pediatric patients, the median age was 5 years (range, 1-9 years). Five had neuroblastoma, 1 had Wilms tumor, and 1 had osteosarcoma. Three had undergone autologous HSCT. The source of isolates was CVC in 6 cases and wound culture in 1. The proportion of CVC-related infections was significantly higher among pediatric patients than adults (85% vs 5%; P ! ). .001
Overall, 13 patients (46%) received chemotherapy in the 3 months preceding the isolation of RGM. Of these, 7 were pe- diatric and 6 were adult. Five (18%) received corticosteroids in the month preceding the isolation of RGM. Four of these were adult and 1 was pediatric. There were no apparent trends in the annual or monthly distribution of RGM infections at MSKCC.
Literature Review
A review of the literature yielded 54 studies describing 313 cancer patients with RGM infection. Of these, 144 patients had pulmonary infection, 144 had bloodstream/catheter-related infection, and 25 had disseminated infection.
Pulmonary infection. Six articles [19] [20] [21] [22] [23] [24] ). P ! .001 Demographic data were reported for 30 of the definitive/ probable cases, including 11 cases from MSKCC. For these, the average age was 55 years (range, 19-84 years). Seventeen (57%) were female. 18 (60%) had a solid tumor, and 12 (40%) had underlying hematologic malignancy, including 8 HSCT recipients (7 allogeneic, 1 not reported). Sixteen (53%) received chemotherapy in the 3 months prior to diagnosis; 9 (35%) of 26 patients for which this was reported received corticosteroids in the month prior to diagnosis.
Twenty-one patients (70%) had underlying lung disease, including chronic obstructive pulmonary disorder, bronchiectasis, prior mycobacterial infection, primary or metastatic lung cancer, radiation fibrosis, or graft-versus-host disease involving the lungs. Among the 11 definitive/probable patients at MSKCC, 7 (64%) had a history of smoking, compared with only 2 (14%) of 14 patients at MSKCC with isolates from other anatomic sources ( ). P p .01 For the 11 definitive/probable patients at MSKCC, additional pathogens were isolated in 10 (91%), including M. avium-intracellulare complex, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Propionibacterium acnes, Nocardia asteroids, and Aspergillus species.
Mycobacterium smegmatis
Antimycobacterial antibiotics were given in 23 of 30 patients with definitive/probable infection with available information. Of these, 13 patients (43%) experienced clinical and/or radiologic improvement. Fourteen (47%) died, with RGM infection contributing to 7 of the deaths.
Bloodstream/CVC-related infection. Including 7 patients from this series, 151 patients with cancer and bloodstream/ catheter-related RGM infection were reported in 36 studies (Table 4) . [4, 17-18, 23, 25-56] . The most common species identified was M. mucogenicum in 46 patients (30%), followed by M. fortuitum in 34 (22%), M. chelonae in 23 (15%), and M. abscessus in 19 (12%). Four studies described outbreaks of RGM infection. Of the outbreaks, 3 were caused by M. mucogenicum (13 cases) and 1 by M. chelonae (4 cases).
Eighty-one patients were male (54%), and 70 (46%) were female. The mean age was 30 years (range, 11 months to 74 years). Of 64 patients whose age was reported, 42 (66%) were pediatric and 22 (34%) were adult.
Of 133 patients whose underlying cancer type was reported, 78 (58%) had a hematologic malignancy. Forty-six were HSCT recipients. Of 26 allogeneic HSCT recipients, 17 were documented to have graft-versus-host disease and 1 had graft failure.
Neutropenia (absolute neutrophil count, !1000 cells/mL) was present at diagnosis in 16 (14%) of 115 patients for which it was reported. Lymphocyte count was known for 33 patients; of these, 19 (57%) were lymphopenic (absolute lymphocyte count, !500 cells/mL). Recent receipt of chemotherapy was reported in 43 patients, 39 (91%) of whom received chemotherapy in the 3 months preceding the diagnosis of RGM infection.
A CVC was present at diagnosis in 136 (97%) of 140 patients for whom information was provided, and the CVC was removed as part of the treatment in 118 (87%). Antibiotics were given in addition to removal of the catheter in 84%. Five patients were treated with antibiotics alone. The median duration of antibiotics was 8 weeks (range, 5 days to 29 weeks). The outcome was described for 141 patients. In 136 patients (96%), the infection resolved after treatment. Five patients died, in- (Table 5) [11, 19, 22-23, 32, 34, 48, 57-68] . M. abscessus was the most common species and was isolated in 12 patients (46%). M. chelonae was isolated in 7 patients (27%), and M. fortuitum was isolated in 6 (23%).
Demographic data were available for 18 adult patients and 5 pediatric patients. For adult patients, the median age was 60 years (range, 22-74 years). Nine were male, and 9 were female. Fifteen (83%) had hematologic neoplasm, including 2 allogeneic HSCT recipients. For the pediatric patients, the median age was 12 years (range, 1.5-18 years). Three were male, and 2 were female. Four had hematologic neoplasm, including 2 allogeneic HSCT recipients.
Overall, 14 of 16 patients with specific information received chemotherapy in the 3 months preceding the diagnosis of RGM infection. Five patients were reported to have received corticosteroids.
The source of isolates was from both blood and skin lesion cultures in 9 patients (35%); both blood and respiratory samples in 6 cases (23%); blood, skin lesion, and respiratory cultures in 2 patients (8%); and only from multiple skin lesions in 5 patients (19%). Overall, 17 patients (65%) had cutaneous evidence of dissemination.
Twenty patients were reported to have been treated with a combination of antibiotics. The outcome was reported in 22 patients. Of these, 15 (68%) died, including 7 who died directly due to RGM infection or with RGM infection as a contributing factor.
DISCUSSION
We describe 341 patients with cancer and positive cultures for RGM, including 28 from our institution. We found that RGM infections in cancer patients constitute 3 distinct syndromes on the basis of the location of infection, with different risk factors, predominant RGM species, and prognoses (Table 6) .
Pulmonary RGM infection typically occurred in older patients, solid cancers predominated, and underlying lung disease was frequently but not invariably present. The most common species involved are M. fortuitum, M. abscessus, and M. chelonae. The frequency of M. abscessus may be underestimated because it was not elevated to species status until 1992, and many older studies did not differentiate it from M. chelonae [69] . Pulmonary RGM infection is serious and difficult to cure, with improvement or resolution in less than one-half of patients with cancer who have definitive/probable infection. Overall, the data for pulmonary RGM infection in cancer patients are comparable to that in noncancer patients, with a similar age at diagnosis, sex distribution, and frequency of underlying lung disease [9] and poor long-term prognosis, with death due to progressive RGM infection occurring in 20% of patients [9, 70] .
Bloodstream/catheter-related RGM infection nearly always occurred in patients who had a CVC. The patients were typically much younger than those with pulmonary infections, with more than one-half being children. Underlying malignancies were commonly hematologic. M. mucogenicum was the predominant species, perhaps due to its association with outbreaks. The prognosis was excellent; however, the CVC was removed in almost all cases, in addition to administration of systemic antibiotics. The 18 patients treated for !1 month had the same outcome as the 14 patients treated for longer periods.
Disseminated RGM infection occurred least commonly and was the most severe. It typically was described in patients with underlying hematologic malignancies, affected any age group, and was frequently associated with recent receipt of chemotherapy. Non-cancer-related conditions in which disseminated RGM infection has been described include renal transplantation, autoimmune diseases, and inborn defects in cytokine pathways, particularly interleukin-12 and interferon-g [11, 71] . It is currently unclear which arm of the immune system is needed to stave off disseminated RGM infection, but given the type of conditions associated with it, profound depression of cellular immunity is likely required. The most common organism associated with disseminated infection was M. abscessus, which is consistent with its apparent higher virulence. Unfortunately, it is also highly resistant, with very few antibiotic choices available for its treatment. Perhaps this explains the dismal prognosis associated with disseminated RGM infection, but it is possible that disseminated RGM infection may merely be a marker of the severity of the underlying disease.
Our study shows several differences in RGM infection between adults and children (Table 7) . Among children, the most common syndrome was bloodstream/catheter-related infection, and there were no cases of definitive/probable pulmonary infection, whereas in adults the frequencies of the 3 syndromes were roughly equal. Accordingly, the predominant RGM species differed, with a higher proportion of M. abscessus among adults and of M. mucogenicum among children. These dissimilarities may be related to differences in the immune system between children and adults and/or to a lower proportion of underlying lung disease among children. Although the reasons remain uncertain, these differences should be taken into consideration whenever a diagnosis of RGM infection is entertained in a patient with cancer.
It is interesting to compare RGM infections in patients with cancer to those in HIV-infected patients. RGM infections are uncommon in HIV-infected patients; in a report from the Centers for Disease Control and Prevention on nontuberculous mycobacteria infection among patients with AIDS in the years 1981-1987, only 10 (0.5%) of 1984 cases of disseminated nontuberculous mycobacteria infection were due to RGM [12] . On reviewing the English-language literature, we only found 34 cases of RGM infection in HIV-infected patients in which clinical data was provided (Table 8 ) [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] . The clinical characteristics of these patients are considerably different from those in patients with cancer. In HIV-infected patients, the major RGM species is M. fortuitum (82% of cases). The predominant clinical manifestation is lymphadenitis in 44% of cases, followed by pulmonary infection in 35% and disseminated infection in 12%. Only 1 patient had a CVC-related infection, perhaps attributable to a lower use of CVCs or a lower proportion of children among HIV-infected patients, compared with patients with cancer. The 2007 American Thoracic Society-Infectious Diseases Society of America guidelines provide comprehensive information on the diagnosis and treatment of nontuberculous mycobacteria infection, including RGM [13] . Because there are substantial differences between RGM and other nontuberculous mycobacteria species in their epidemiology, clinical manifestations, and treatment, we believe that future guidelines on this topic should address RGM separately from other nontuberculous mycobacteria species. Our study shows that a useful way of categorizing RGM infections in patients with cancer is by clinical syndrome. If our data are also applicable to RGM infections in other populations, we would also recommend that future guidelines address RGM infections by syndrome rather than by species.
Our study has several limitations. First, we obtained data from cases reported in the literature. It is possible that these do not reflect the overall characteristics of RGM infection in patients with cancer. However, the features of the cases described in the literature are largely similar to those of our own case series. We therefore believe that cases described in the literature truly represent this population. Second, the presence of disseminated infection may have been underestimated, because some patients classified as having pulmonary or bloodstream infection could have had undiagnosed dissemination. We attempted to minimize this possibility by excluding any cases where there was a question of dissemination; nevertheless, it is still possible that some cases were misclassified. Finally, our study did not have a control group. We could not therefore assign odds ratios to specific risk factors.
In summary, RGM infections in patients with cancer comprise 3 distinct syndromes. Pulmonary RGM infections are commonly associated with underlying structural pulmonary abnormalities. Bloodstream infections are strongly associated with the presence of a CVC; additionally, an underlying immune dysfunction is commonly found. Disseminated disease is almost invariably associated with severe underlying immunodeficiency and has a poor prognosis. Management of these infections should take these differences into account.
